Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147


Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials.

Byrne RA, Cassese S, Windisch T, King LA, Joner M, Tada T, Mehilli J, Pache J, Kastrati A.

EuroIntervention. 2013 Nov;9(7):797-802. doi: 10.4244/EIJV9I7A132.


Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.

Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schömig A, Kastrati A; ISAR-DESIRE 2 Investigators..

J Am Coll Cardiol. 2010 Jun 15;55(24):2710-6. doi: 10.1016/j.jacc.2010.02.009. Epub 2010 Mar 11.


Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.

Kufner S, Byrne RA, de Waha A, Schulz S, Joner M, Laugwitz KL, Kastrati A; Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2, (ISAR-DESIRE 2) Investigators..

Cardiovasc Revasc Med. 2014 Mar;15(2):69-75. doi: 10.1016/j.carrev.2014.02.001. Epub 2014 Feb 15.


Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis.

Ota H, Mahmoudi M, Torguson R, Satler LF, Suddath WO, Pichard AD, Waksman R.

Cardiovasc Revasc Med. 2015 Apr-May;16(3):151-5. doi: 10.1016/j.carrev.2015.02.005. Epub 2015 Feb 26.


One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.

Chevalier B, Moulichon R, Teiger E, Brunel P, Metzger JP, Pansieri M, Carrie D, Stoll HP, Wittebols K, Spaulding C, Fajadet J; Cristal Investigators..

J Interv Cardiol. 2012 Dec;25(6):586-95. doi: 10.1111/j.1540-8183.2012.00769.x. Epub 2012 Sep 20.


Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.

Kim YH, Park SW, Lee CW, Hong MK, Gwon HC, Jang Y, Lee MM, Koo BK, Oh DJ, Seung KB, Tahk SJ, Yoon J, Park SJ.

Catheter Cardiovasc Interv. 2006 Feb;67(2):181-7.


A comparison of angiographic and clinical outcomes after sirolimus-eluting versus paclitaxel-eluting stents for the treatment of in-stent restenosis.

Li JJ, Xu B, Yang YJ, Ma WH, Chen JL, Qiao SB, Qin XW, Yao M, Liu HB, Wu YJ, Yuan JQ, Chen J, You SJ, Dai J, Xia R, Gao RL.

Chin Med J (Engl). 2006 Jul 5;119(13):1059-64.


The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.

Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW; Interventional Cardiologists of the Thoraxcenter..

JACC Cardiovasc Interv. 2010 Oct;3(10):1051-8. doi: 10.1016/j.jcin.2010.08.003.


5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.

Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R.

J Am Coll Cardiol. 2009 Sep 1;54(10):894-902. doi: 10.1016/j.jacc.2009.04.077.


Sirolimus-eluting stent showed better one-year outcomes than paclitaxel-eluting stent in a real life setting of coronary intervention in Koreans.

Suh JW, Park JS, Cho HJ, Kim MS, Kang HJ, Cho YS, Koo BK, Chung WY, Youn TJ, Chae IH, Choi DJ, Kim HS, Sohn DW, Oh BH, Park YB.

Int J Cardiol. 2007 Apr 12;117(1):31-6. Epub 2007 Feb 8.


Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.

Circulation. 2012 Jun 12;125(23):2873-91. doi: 10.1161/CIRCULATIONAHA.112.097014. Epub 2012 May 14.


Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.

Almalla M, Schröder JW, Pross V, Marx N, Hoffmann R.

Coron Artery Dis. 2013 Mar;24(2):165-70. doi: 10.1097/MCA.0b013e32835c8fb2.


Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.

Markovic S, Paliskyte R, Rottbauer W, Wöhrle J.

Cardiovasc Revasc Med. 2012 Nov-Dec;13(6):307-10. doi: 10.1016/j.carrev.2012.09.003.


3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.

Holmes DR Jr, Teirstein PS, Satler L, Sketch MH Jr, Popma JJ, Mauri L, Wang HP, Schleckser PA, Cohen SA; SISR Investigators..

JACC Cardiovasc Interv. 2008 Aug;1(4):439-48. doi: 10.1016/j.jcin.2008.05.010.


Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.

Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig A; LEFT-MAIN Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study Investigators..

J Am Coll Cardiol. 2009 May 12;53(19):1760-8. doi: 10.1016/j.jacc.2009.01.035.


Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.

Airoldi F, Briguori C, Iakovou I, Stankovic G, Biondi-Zoccai G, Carlino M, Chieffo A, Montorfano M, Cosgrave J, Michev I, Rogacka R, Sangiorgi GM, Colombo A.

Am J Cardiol. 2006 Apr 15;97(8):1182-7. Epub 2006 Mar 9.


Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.

Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Schüpke S, Hoppmann P, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A, Byrne RA; ISAR-DESIRE 3 Investigators..

JACC Cardiovasc Interv. 2015 Jun;8(7):877-84. doi: 10.1016/j.jcin.2015.01.031. Epub 2015 May 20.


Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.

Fan L, Chen LL, Lin CG, Peng YF, Zheng XC, Luo YK, Zhang FL, Chen JH, Yan XP, Huang ZR.

Chin Med J (Engl). 2008 Aug 20;121(16):1518-23.


Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.

Barlis P, Kaplan S, Dimopoulos K, Ferrante G, Di Mario C.

Cardiology. 2008;111(4):270-6. doi: 10.1159/000128602. Epub 2008 May 2.


Supplemental Content

Support Center